← Back to Search

Non-invasive Brain Stimulation

tDCS for Speech Impairment After Stroke

N/A
Recruiting
Led By Adam Buchwald, MD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinical diagnosis of apraxia of speech
A minimum of six months post-stroke
Must not have
Past history of seizures or unexplained spells of loss of consciousness.
Diagnosis of laryngeal voice disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 6 months
Awards & highlights

Summary

This trial is testing whether combining a gentle brain stimulation technique called tDCS with regular speech therapy can better help people who have trouble speaking due to brain injury. tDCS uses a mild electrical current to help the brain learn and adapt, which has been successful in other types of stroke recovery. tDCS has been shown to be effective in improving language recovery in post-stroke aphasia.

Who is the study for?
This trial is for right-handed, English-speaking individuals who have had a stroke at least six months ago and now have apraxia of speech. They must not have any voice disorders, other speech impairments from before the stroke, or risk factors that make tDCS unsafe like skin damage where the device goes, implants affected by electricity or magnets, metal inside their body, or a family history of epilepsy.
What is being tested?
The study tests if adding brain stimulation with a Soterix low-intensity stimulator to regular speech therapy helps recovery in people with speech issues after a stroke. Some participants will get real stimulation (tDCS), while others receive sham treatment as a comparison; this is decided randomly.
What are the potential side effects?
tDCS is generally safe and well-tolerated. Possible side effects include mild tingling on the scalp, slight itching under the electrode site during stimulation, brief headache or fatigue post-treatment. Serious risks are rare but can involve seizures.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with apraxia of speech.
Select...
It has been at least 6 months since my stroke.
Select...
I had a stroke in the left side of my brain.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have had seizures or unexplained fainting spells.
Select...
I have been diagnosed with a voice disorder affecting my larynx.
Select...
I have damaged skin where the stimulation device would be placed.
Select...
I have difficulty speaking clearly.
Select...
I had speech problems before my stroke.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in accuracy in recordings from tasks from baseline to post treatment

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active StimulationExperimental Treatment2 Interventions
crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
Group II: Sham StimulationPlacebo Group2 Interventions
crossover design such that each participant receives behavioral treatment twice - once with active stimulation and once with sham stimulation - in order to evaluate differences in improvement based on treatment condition.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sham
2013
Completed Phase 3
~2090

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment that delivers low-intensity electrical currents to the scalp, aiming to enhance neural plasticity and facilitate motor learning. This mechanism is particularly relevant for Apraxia of Speech (AOS) patients, as it can improve the brain's ability to reorganize and strengthen the neural pathways involved in speech production. By combining tDCS with effective behavioral speech therapy, patients may experience improved speech motor control and communication abilities, which are critical for their daily interactions and overall quality of life.

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,397 Previous Clinical Trials
861,818 Total Patients Enrolled
National Institute on Deafness and Other Communication Disorders (NIDCD)NIH
348 Previous Clinical Trials
180,713 Total Patients Enrolled
6 Trials studying Apraxia of Speech
280 Patients Enrolled for Apraxia of Speech
Adam Buchwald, MDPrincipal InvestigatorNYU Langone Health

Media Library

Soterix 1x1 line tDCS low-intensity stimulator (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT03452202 — N/A
Apraxia of Speech Research Study Groups: Active Stimulation, Sham Stimulation
~6 spots leftby Oct 2026